[EN] SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS 2,3-DIHYDROBENZOFURANYLE SUBSTITUÉS ET LEURS UTILISATIONS
申请人:KARYOPHARM THERAPEUTICS INC
公开号:WO2014085607A1
公开(公告)日:2014-06-05
The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
[EN] DIHYDROBENZOFURAN COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES DIHYDROBENZOFURANE ET LEURS UTILISATIONS
申请人:PFIZER PROD INC
公开号:WO2006000902A1
公开(公告)日:2006-01-05
Dihydrobenzofuran compounds of Formula (I), including salts, prodrugs, hydrates and solvates thereof, that act as 5-HT2 receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein. Formula (I).
Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
申请人:KARYOPHARM THERAPEUTICS INC.
公开号:US20160221994A1
公开(公告)日:2016-08-04
The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.